MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Market Cap 2011-2026 | ANIX
As of March 17, 2026 Anixa Biosciences has a market cap of $ 93.5 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 K | 70.8 K | 151 K | 137 K | 60.1 M | 58.7 M | 75.8 M | 69.1 M | 30.5 M | 54.7 M | 27 M | 40.7 M | 45.4 M | 39.9 M | 23.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 75.8 M | 70.8 K | 35.1 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
608 M | $ 8.98 | 1.18 % | $ 598 M |  USA |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 13.87 | 1.61 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
709 M | $ 26.0 | 0.64 % | $ 722 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
25.5 B | $ 68.09 | 2.64 % | $ 26.6 B | USA |
 |
Guardant Health
GH
|
13.4 B | $ 88.7 | 1.74 % | $ 11.1 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 155.4 | 2.26 % | $ 7.7 B | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.57 | 1.44 % | $ 936 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 101.48 | 3.96 % | $ 8.37 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 169.45 | 2.77 % | $ 29.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | $ 103.94 | 0.08 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
467 M | $ 15.65 | 4.65 % | $ 473 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 17.5 | 1.21 % | $ 2.27 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.37 | 2.85 % | $ 2.03 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 194.76 | 1.76 % | $ 139 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.4 | 3.16 % | $ 420 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 121.73 | 2.05 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 199.39 | 0.23 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
42 B | $ 113.69 | 1.66 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.12 | 0.9 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 9.28 | 10.24 % | $ 263 M | Israel |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 78.71 | 0.26 % | $ 5.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 457.78 | 0.91 % | $ 13.2 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 218.18 | 1.62 % | $ 25.1 B |  Schweiz |
 |
Celcuity
CELC
|
399 M | $ 114.64 | -0.23 % | $ 4.52 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Twist Bioscience Corporation
TWST
|
1.56 B | $ 46.28 | 2.82 % | $ 2.77 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 18.07 | 3.85 % | $ 404 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.41 | 2.06 % | $ 1.08 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
5.31 B | $ 201.38 | 1.87 % | $ 19.8 B | USA |